Lupin's Novel SOS1 Inhibitor LNP8701 Shows Promising Safety Profile in Phase 1 Solid Tumor Trial
核心洞察
Lupin's investigational oral drug LNP8701, a SOS1 (搜索) inhibitor targeting RAS (搜索) activation, demonstrated favorable safety and tolerability in a Phase 1 study of 20 stage IV cancer (搜索) patients.
The multicenter trial showed that LNP8701 was well tolerated across all tested dosing levels, with five patients achieving stable disease and one patient showing partial response.
Two patients completed 12 cycles of treatment and one patient completed 14 cycles, all with stable disease, indicating potential for sustained therapeutic benefit in difficult-to-treat cancers.
Mumbai-based Lupin Limited has announced positive results from its Phase 1 study of LNP8701, an investigational oral SOS1 (搜索) inhibitor designed to treat solid tumors (搜索) in patients who have exhausted existing standard treatment options or have no approved treatment options. The findings were presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting in Chicago.
Study Design and Patient Population
The multicenter, open-label Phase 1a trial enrolled 20 patients with stage IV cancer (搜索) and a median age of 50.5 years. LNP8701 was administered once daily for cycles of 28 days each, with the study designed to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy of the novel compound.
LNP8701 works by blocking Son of Sevenless 1 (SOS1 (搜索)) mediated RAS (搜索) activation, thereby limiting oncogenic signaling that promotes tumor growth. This mechanism of action represents a targeted approach to disrupting cancer cell proliferation pathways.
Safety and Tolerability Profile
The study demonstrated that LNP8701 was well tolerated across all tested dosing levels with a desirable safety profile. The most common adverse events reported were anemia (搜索), vomiting, and pain in extremity. Current data suggest that the drug maintains consistent safety characteristics throughout the treatment duration.
Efficacy Outcomes
The preliminary efficacy findings showed encouraging anti-tumor activity. Five patients achieved stable disease as their best overall response, while one patient demonstrated a partial response during the study period. Notably, treatment duration varied significantly among patients, with two patients completing 12 cycles (equivalent to one year) of LNP8701 monotherapy and one patient completing 14 cycles, all while maintaining stable disease.
However, fifteen patients discontinued therapy due to disease progression, highlighting the challenges inherent in treating advanced solid tumors (搜索) in heavily pretreated patient populations.
Clinical Significance and Future Directions
"The findings from the ongoing Phase 1 study highlight the emerging potential of LNP8701 and signal progress in our pursuit of novel therapies for difficult-to-treat cancers," said Vinita Gupta, CEO of Lupin Limited. "We are encouraged by this momentum and remain committed to transforming scientific discovery into meaningful patient outcomes."
The company plans to continue studying LNP8701's efficacy in its Phase 1b trial in India and will explore the drug's potential both as a monotherapy and as part of combination therapy regimens. This approach reflects the growing trend in oncology toward personalized treatment strategies that may enhance therapeutic outcomes for patients with limited treatment options.
The study results were published in the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology track at ASCO 2026, with the abstract available under clinical trial registration number CTRI/2024/08/072373.